Dr Colin Petrie
- Honorary Clinical Senior Lecturer (School of Cardiovascular & Metabolic Health)
The University of Glasgow uses cookies for analytics. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Hotjar and Clarity help us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
Cleland, J. G.F. et al. (2024) Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial. European Heart Journal, (doi: 10.1093/eurheartj/ehae086) (PMID:38446126) (Early Online Publication)
Lee, M. M.Y. et al. (2022) Effect of empagliflozin on kidney biochemical and imaging outcomes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 146(4), pp. 364-367. (doi: 10.1161/CIRCULATIONAHA.122.059851) (PMID:35877829)
Lee, M. M.Y. et al. (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 143(6), pp. 516-525. (doi: 10.1161/CIRCULATIONAHA.120.052186) (PMID:33186500) (PMCID:PMC7864599)
Maznyczka, A. M. et al. (2020) Comparative significance of invasive measures of microvascular injury in acute myocardial infarction. Circulation: Cardiovascular Interventions, 13(5), e008505. (doi: 10.1161/CIRCINTERVENTIONS.119.008505) (PMID:32408817) (PMCID:PMC7237023)
Maznyczka, A. M. et al. (2020) One-year outcomes after low-dose intracoronary alteplase during primary percutaneous coronary intervention. The T-TIME randomized trial. Circulation: Cardiovascular Interventions, 13(2), e008855. (doi: 10.1161/CIRCINTERVENTIONS.119.008855) (PMID:32069113)
Cleland, J. G.F. et al. (2024) Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial. European Heart Journal, (doi: 10.1093/eurheartj/ehae086) (PMID:38446126) (Early Online Publication)
Lee, M. M.Y. et al. (2022) Effect of empagliflozin on kidney biochemical and imaging outcomes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 146(4), pp. 364-367. (doi: 10.1161/CIRCULATIONAHA.122.059851) (PMID:35877829)
Lee, M. M.Y. et al. (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 143(6), pp. 516-525. (doi: 10.1161/CIRCULATIONAHA.120.052186) (PMID:33186500) (PMCID:PMC7864599)
Maznyczka, A. M. et al. (2020) Comparative significance of invasive measures of microvascular injury in acute myocardial infarction. Circulation: Cardiovascular Interventions, 13(5), e008505. (doi: 10.1161/CIRCINTERVENTIONS.119.008505) (PMID:32408817) (PMCID:PMC7237023)
Maznyczka, A. M. et al. (2020) One-year outcomes after low-dose intracoronary alteplase during primary percutaneous coronary intervention. The T-TIME randomized trial. Circulation: Cardiovascular Interventions, 13(2), e008855. (doi: 10.1161/CIRCINTERVENTIONS.119.008855) (PMID:32069113)